$3.72
21.35% yesterday
Nasdaq, Apr 07, 10:00 pm CET
ISIN
US0070251097
Symbol
ADTX
Sector
Industry

Aditx Therapeutics Inc Stock price

$3.72
-9.16 71.11% 1M
-368.78 99.00% 6M
-43.73 92.16% YTD
-31,096.28 99.99% 1Y
-8,599,996.28 100.00% 3Y
-101,199,996.28 100.00% 5Y
-101,199,996.28 100.00% 10Y
Nasdaq, Closing price Mon, Apr 07 2025
-1.01 21.35%
ISIN
US0070251097
Symbol
ADTX
Sector
Industry

Key metrics

Market capitalization $4.31m
Enterprise Value $18.19m
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 139.92
P/S ratio (TTM) P/S ratio 33.15
P/B ratio (TTM) P/B ratio 0.97
Revenue growth (TTM) Revenue growth -79.23%
Revenue (TTM) Revenue $130.00k
EBIT (operating result TTM) EBIT $-27.86m
Free Cash Flow (TTM) Free Cash Flow $-16.76m
Cash position $830.00k
EPS (TTM) EPS $-161,133.91
Short interest 9.30%
Show more

Is Aditx Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Aditx Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Aditx Therapeutics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Aditx Therapeutics Inc:

Buy
100%

Financial data from Aditx Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.13 0.13
80% 80%
100%
- Direct Costs 1.24 1.24
5% 5%
954%
-1.11 -1.11
71% 71%
-854%
- Selling and Administrative Expenses 15 15
14% 14%
11,731%
- Research and Development Expense 11 11
54% 54%
8,377%
-27 -27
7% 7%
-20,962%
- Depreciation and Amortization 0.62 0.62
15% 15%
477%
EBIT (Operating Income) EBIT -28 -28
7% 7%
-21,434%
Net Profit -34 -34
6% 6%
-26,500%

In millions USD.

Don't miss a Thing! We will send you all news about Aditx Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aditx Therapeutics Inc Stock News

Neutral
Business Wire
6 days ago
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that Don Cilla, Pharm.D., M.B.A., President and CEO of Appili Therapeutics Inc. ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, will be joining at ...
Neutral
Business Wire
11 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX), (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced that today's Aditxt Weekly Update will focus on the recent acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. (“Pearsanta”). The proprietary technology is based on adductomics and is designed to asses...
Neutral
PRNewsWire
15 days ago
-- 2024 Net Sales Increased 6% to $19.4 Million  -- -- Total Operating Expense Reduced 27% from 2023 Levels,  Excluding Non-cash Amortization Expense  -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO , March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosci...
More Aditx Therapeutics Inc News

Company Profile

ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.

Head office United States
CEO Amro Albanna
Employees 26
Founded 2017
Website www.aditxt.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today